Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
Key facts
- Where
- Kartasura, IndonesiaSee the site
- Phase
- Phase 4
Where in Indonesia
- UNS HospitalKartasura, IndonesiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Evi Liliek Wulandari
- Trial code
- NCT07259512
- Record updated
- 10 December 2025
- Original description
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.Read full original descriptionShow less
Comparative Effects of Single Versus Twice-Daily Ramipril Dosing on Renal Function in Patients With Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction: Evaluation of Plasma Renin Activity, Malondialdehyde, Interleukin-6, Albuminuria, and Cystatin C
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
Inclusion: Female or Male with age >18 years old; Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction < 40%).
Exclusion: Receiving hemodialysis therapy; Receiving sacubitril-valsartan therapy; Receiving ARB therapy; History of intolerance to ACE inhibitors; History of angioedema to ACE inhibitors; Refractory hyperkalemia; Pregnancy; Hypotension with blood pressure <90/60, or patients in shock.